Pfizer saw an all-time high with its annual revenue as it raked in $100.3 billion. For 2023, the vaccine-maker said it expects to make between $67 billion and $71 billion amid waning demand for its COVID-19 vaccine and COVID-19 drug Paxlovid.
Johnson & Johnson saw sales of $94.9 billion, a 1.3 percent increase from its 2021 figure. About half of those earnings are from the U.S. Overall, its pharmaceutical business made $52.6 billion, its medical tech segment earned $27.4 billion and its consumer health business got $15 billion.
Merck‘s sales totaled $59.3 billion, amounting to a 22 percent increase since 2021. Some of its best-selling products included its COVID-19 antiviral Lagevrio and cancer drug Keytruda.
Bristol-Myers Squibb reported earning $46.2 billion. When adjusted to foreign exchange rates, it made 3 percent more than 2021. In the U.S., its revenue increased 9 percent to $31.8 billion.
Biogen earned $10.2 billion in 2022, a 7.4 percent decrease from the year prior. The company said its losses were “driven primarily by cost saving initiatives.” Biogen said investors should “expect mid-single digit revenue decline” in 2023.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.